Topical roflumilast formulation having improved delivery and plasma half life
AssigneeArcutis Biotherapeutics, Inc.
InventorDavid W. Osborne
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods for improving the therapeutic outcome of treatment with roflumilast. The therapeutic outcome is improved by consistent delivery and/or a longer plasma half-life of a topically administered roflumilast composition. The roflumilast composition preferably includes dicetyl phosphate, ceteth-10 phosphate, diethylene glycol monoethyl ether, and/or hexylene glycol.
Claims20
A method for improving the therapeutic outcome of treatment with roflumilast, comprising topically administering once daily a composition comprising diethylene glycol monoethyl ether, cetearyl alcohol, dicetyl phosphate, ceteth-10 phosphate and roflumilast to a patient in need of such treatment, wherein said patient misses at least one dose but no more than two consecutive doses, and the plasma concentration of roflumilast decreases by less than 50%.
A method for improving the therapeutic outcome of treatment with roflumilast, comprising topically administering once daily a composition comprising diethylene glycol monoethyl ether, a phosphate ester surfactant blend comprising dicetyl phosphate, ceteth-10 phosphate and cetearyl alcohol, and roflumilast to a patient in need of such treatment once daily, wherein when said patient misses at least one dose but no more than two consecutive doses, the plasma concentration of roflumilast decreases by less than 50%.
Dependencies are inferred from the claim text.